Oppenheimer Reiterates Outperform on UroGen Pharma, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has reiterated an Outperform rating for UroGen Pharma (NASDAQ:URGN) and maintained a $40 price target.
October 16, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reiterated its Outperform rating for UroGen Pharma, maintaining a $40 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $40 price target by Oppenheimer suggests positive sentiment and confidence in UroGen Pharma's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100